Basal insulin analogs are recognized as an effective method of achieving and maintaining glycemic control for patients with type 2 diabetes.However, due to the progressive nature of the disease, some individuals may require additional ways to maintain their glycemic goals.Intensification in these circumstances has traditionally been achieved by the addition of short-acting insulin to cover postprandial glucose excursions that are not targeted by basal insulin.However,intensive insulin regimens are associated with a higher risk of hypoglycemia and weight gain, which can contribute to a greater burden on patients.The combination of basal insulin with a glucagon-like peptide-1 (GLP-1) mimetic is a potentially attractive solution to this problem for some patients with type 2 diabetes.GLP-1 mimetics target postprandial glucose and should complement the activity of basal insulins;they are also associated with a relatively low risk of associated hypoglycemia and moderate, but significant, weight loss.Evidence from recent studies mostly suggests that basal insulins in combination with GLP-1 mimetics do provide improvements in A1 c and postprandial glucose with concomitant weight loss and no marked increase in the risk of hypoglycemia.Among various GLP-1 available for clinical treatment or still under development some appear better suited than others to be used in combination with basal insulin.Studies conducted to date are very supportive of the advantage for the combination of basal insulin with GLP-1, and a potentail treatment paradigm is likely to be generated from those scientific evidences.